Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)
Phase of Trial: Phase I
Latest Information Update: 11 May 2015
At a glance
- Drugs Idalopirdine (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacokinetics
- Sponsors Lundbeck A/S
- 06 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 02 Mar 2015 New trial record